The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).
 
Silke Gillessen
Consulting or Advisory Role - Active Biotech (Inst); Advanced Accelerator Applications; Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac (Inst); Curevac (Inst); Ferring (Inst); Ferring (Inst); Innocrin Pharma (Inst); Janssen (Inst); MaxiVax; Novartis (Inst); Orion; Roche; Sanofi
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Other Relationship - Nektar; ProteoMediX
 
Roger Anton Fredy Von Moos
Honoraria - Bayer/Onyx; Roche
Consulting or Advisory Role - Amgen (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche/Genentech (Inst)
Research Funding - Bayer/Onyx (Inst); Merck Serono (Inst)
Other Relationship - Pfizer
 
Stefanie Hayoz
No Relationships to Disclose
 
Hanne Hawle
No Relationships to Disclose
 
Richard Cathomas
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer (Inst); Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Novartis (Inst); Pfizer; Roche (Inst); Sanofi (Inst)
 
Christian Alexander Rothermundt
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Research Funding - Astellas Pharma (Inst)
 
Sandro Anchisi
No Relationships to Disclose
 
Andreas Mueller
No Relationships to Disclose
 
Tobias Wehrhahn
No Relationships to Disclose
 
Henning Burmeister
No Relationships to Disclose
 
Susanna Stoll
No Relationships to Disclose
 
Anna Llado
No Relationships to Disclose
 
Markus M. Borner
No Relationships to Disclose
 
Augusto Pedrazzini
Honoraria - Roche
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Gilead Sciences
 
Urs Sebastian Huber-Tribolet
No Relationships to Disclose
 
Pierre Oliver Bohanes
Honoraria - Abbvie; Lilly; Merck Serono; Sanofi
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly
 
Ralph C. Winterhalder
No Relationships to Disclose
 
Andrea Corinne Fuhrer
No Relationships to Disclose
 
Corinne Schaer
No Relationships to Disclose
 
Arnoud J. Templeton
Honoraria - Astellas Medivation
Consulting or Advisory Role - Astellas Medivation; Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; Sanofi